Cargando…
Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
BACKGROUND: Acute lung injury (ALI) is a common complication of sepsis with poor effective interventions. Huashibaidu formula (HSBD) showed good therapeutic effects in treating coronavirus disease 2019 (COVID-19) patients. PURPOSE: This study was designed to investigate the therapeutic potential and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier GmbH.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674563/ https://www.ncbi.nlm.nih.gov/pubmed/36610129 http://dx.doi.org/10.1016/j.phymed.2022.154549 |
_version_ | 1784833182752833536 |
---|---|
author | Zhang, Fangbo Guo, Feifei Zhang, Yi Xu, He Liu, Yuling Lin, Longfei Li, Hui Yang, Hongjun Huang, Luqi |
author_facet | Zhang, Fangbo Guo, Feifei Zhang, Yi Xu, He Liu, Yuling Lin, Longfei Li, Hui Yang, Hongjun Huang, Luqi |
author_sort | Zhang, Fangbo |
collection | PubMed |
description | BACKGROUND: Acute lung injury (ALI) is a common complication of sepsis with poor effective interventions. Huashibaidu formula (HSBD) showed good therapeutic effects in treating coronavirus disease 2019 (COVID-19) patients. PURPOSE: This study was designed to investigate the therapeutic potential and precise mechanism of HSBD against sepsis-induced ALI based on network pharmacology and animal experiments. MATERIALS AND METHODS: Network pharmacology was used to predict the possible mechanism of HSBD against sepsis. Next, a sepsis-induced ALI rat model via intraperitoneal lipopolysaccharide (LPS) was constructed to evaluate the level of inflammatory cytokines and the degree of lung injury. The expression of inflammation-related signaling pathways, including TLR4/NF-κB and PI3K/Akt was determined by western blot. RESULTS: Network pharmacology analysis indicated that HSBD might have a therapeutic effect on sepsis mainly by affecting inflammatory and immune responses. Animal experiments demonstrated that HSBD protected the lung tissue from LPS-induced injury, and inhibited the levels of inflammatory cytokines such as interleukin (IL)-1β, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ and tumor necrosis factor (TNF)-α in the serum and IL-1β, IL-5, IL-6, IL-18, GM-CSF, IFN-γ and TNF-α in the lung tissue. Western blot results revealed that HSBD downregulated the expression of TLR4/NF-κB and upregulated the expression of PI3K/Akt. CONCLUSION: The therapeutic mechanism of HSBD against sepsis-induced ALI mainly involved suppressing cytokine storms and relieving inflammatory symptoms by regulating the expression of TLR4/NF-κB and PI3K/Akt. Our study provides a scientific basis for the mechanistic investigation and clinical application of HSBD in the treatment of sepsis and COVID-19. |
format | Online Article Text |
id | pubmed-9674563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Published by Elsevier GmbH. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96745632022-11-21 Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 Zhang, Fangbo Guo, Feifei Zhang, Yi Xu, He Liu, Yuling Lin, Longfei Li, Hui Yang, Hongjun Huang, Luqi Phytomedicine Original Article BACKGROUND: Acute lung injury (ALI) is a common complication of sepsis with poor effective interventions. Huashibaidu formula (HSBD) showed good therapeutic effects in treating coronavirus disease 2019 (COVID-19) patients. PURPOSE: This study was designed to investigate the therapeutic potential and precise mechanism of HSBD against sepsis-induced ALI based on network pharmacology and animal experiments. MATERIALS AND METHODS: Network pharmacology was used to predict the possible mechanism of HSBD against sepsis. Next, a sepsis-induced ALI rat model via intraperitoneal lipopolysaccharide (LPS) was constructed to evaluate the level of inflammatory cytokines and the degree of lung injury. The expression of inflammation-related signaling pathways, including TLR4/NF-κB and PI3K/Akt was determined by western blot. RESULTS: Network pharmacology analysis indicated that HSBD might have a therapeutic effect on sepsis mainly by affecting inflammatory and immune responses. Animal experiments demonstrated that HSBD protected the lung tissue from LPS-induced injury, and inhibited the levels of inflammatory cytokines such as interleukin (IL)-1β, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ and tumor necrosis factor (TNF)-α in the serum and IL-1β, IL-5, IL-6, IL-18, GM-CSF, IFN-γ and TNF-α in the lung tissue. Western blot results revealed that HSBD downregulated the expression of TLR4/NF-κB and upregulated the expression of PI3K/Akt. CONCLUSION: The therapeutic mechanism of HSBD against sepsis-induced ALI mainly involved suppressing cytokine storms and relieving inflammatory symptoms by regulating the expression of TLR4/NF-κB and PI3K/Akt. Our study provides a scientific basis for the mechanistic investigation and clinical application of HSBD in the treatment of sepsis and COVID-19. Published by Elsevier GmbH. 2023-01 2022-11-19 /pmc/articles/PMC9674563/ /pubmed/36610129 http://dx.doi.org/10.1016/j.phymed.2022.154549 Text en © 2022 Published by Elsevier GmbH. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Zhang, Fangbo Guo, Feifei Zhang, Yi Xu, He Liu, Yuling Lin, Longfei Li, Hui Yang, Hongjun Huang, Luqi Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 |
title | Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 |
title_full | Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 |
title_fullStr | Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 |
title_full_unstemmed | Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 |
title_short | Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 |
title_sort | huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: implications for treatment of covid-19 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674563/ https://www.ncbi.nlm.nih.gov/pubmed/36610129 http://dx.doi.org/10.1016/j.phymed.2022.154549 |
work_keys_str_mv | AT zhangfangbo huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT guofeifei huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT zhangyi huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT xuhe huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT liuyuling huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT linlongfei huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT lihui huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT yanghongjun huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 AT huangluqi huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19 |